

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

RESULTS OF ANNUAL GENERAL MEETING

The Board is pleased to announce that all the resolutions as set out in the notice of AGM dated 8 May 2025 were duly passed at the AGM held on 24 June 2025.

RESULTS OF THE AGM

Reference is made to the notice of the annual general meeting (the “AGM”) of the Company (the “Notice”) dated 8 May 2025. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Notice. The board of directors of the Company is pleased to announce that all the resolutions as set out in the Notice were duly passed by way of poll at the AGM held on 24 June 2025.

As at the date of the AGM, the Company had 2,133,900,000 shares in issue including 697,500,000 domestic shares and 1,436,400,000 H shares. Shareholders of the Company holding a total of 1,986,761,664 shares of the Company were entitled to attend and vote for or against all the resolutions set out in the Notice by way of poll at the AGM. There were no shares entitling the shareholders of the Company to attend and vote only against any of the resolutions at the AGM.

Details of the poll result in respect of resolutions proposed at the AGM were as follows:

		Number of Shares Represented by Votes (%)		Total Number of Shares
		For	Against	
ORDINARY RESOLUTIONS				
1.	To consider and, if thought fit, approve the audited consolidated accounts of the Group for the year ended 31 December 2024.	665,150,000 shares 100%	0 shares 0%	665,150,000 shares
2.	To consider and, if thought fit, approve the report of the directors of the Company.	665,150,000 shares 100%	0 shares 0%	665,150,000 shares
3.	To consider and, if thought fit, approve the report of the Supervisory Committee of the Company.	665,150,000 shares 100%	0 shares 0%	665,150,000 shares
4.	To consider and, if thought fit, approve the proposal of appointing Fan, Chan & Co. Limited as auditor of the Company for the financial year of 2025 and authorize the Directors of the Company to fix their remuneration.	665,150,000 shares 100%	0 shares 0%	665,150,000 shares
SPECIAL RESOLUTIONS [#]				
5.	To grant to the Board a general mandate to issue, allot and deal with additional Domestic Shares/ H Shares not to exceed 20% of Domestic Shares in issue and 20% of H Shares in issue of the Company, and to authorize the Board to make such amendments to the articles of association of the Company as it thinks fit so as to reflect the new share capital structure subsequent to allotment and issue of additional Shares.	665,150,000 shares 100%	0 shares 0%	665,150,000 shares
6.	To approve the proposed amendments to the existing articles of association of the Company and the adoption of the amended articles of association of the Company.	665,150,000 shares 100%	0 shares 0%	665,150,000 shares

[#] The description of these resolutions is by way of summary only. The full text appears in the Notice of the AGM of the Company for the year 2024.

As more than half of the votes present at the AGM either in person or by proxy were cast in favor of the above ordinary resolutions numbered (1) to (4), these resolutions were duly passed as ordinary resolutions.

As more than two-thirds of the votes present at the AGM either in person or by proxy were cast in favor of the above special resolution numbered (5) and (6), these resolutions were duly passed as special resolutions.

Ms. Sun Li as the executive Director, Mr. He Xin and Ms. Li Xueying as the non-executive Directors and Mr. Wang Yongkang, Ms. Gao Chun and Mr. Tu Xiangzhen as the independent non-executive Directors attended the AGM.

RSM China CPA LLP (容誠會計師事務所(特殊普通合夥)), an independent external accountants firm acted as the scrutineer for the purpose of vote-taking at the AGM.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the People's Republic of China
24 June 2025

As at the date of this announcement, the executive director of the Company is Sun Li; the non-executive directors of the Company are He Xin, Li Ximing and Li Xueying; the independent non-executive directors of the Company are Tu Xiangzhen, Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make this announcement or any statement herein misleading.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the "Latest Company Announcements" page for seven (7) days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.